Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics

Carine Ngo; Léo Colmet-Daage; Julien Vibert; Clémence Hénon; Daniel Pissaloux; Alexander Valent; Jia Xiang Jin; Riwan Brillet; Julien Masliah-Planchon; Gaëlle Pierron; Ludovic Lacroix; Etienne Rouleau; Cyril Roussel-Simonin; Lilian Lecorgne; Clémence Astier; Marlène Garrido; Rastislav Bahleda; Benjamin Verret; Axel Le Cesne; Charles Honore; Matthieu Faron; Wolf Herman Fridman; Catherine Sautès-Fridman; Jean-Michel Coindre; Jean-Yves Scoazec; Joshua J Waterfall; Franck Bourdeaut; Thomas G. P. Grünewald; Jean-Yves Blay; Franck Tirode; Sophie Postel-Vinay

doi:10.1002/cac2.70077

Cancer Communications ›› 2025, Vol. 45 ›› Issue (12) :1760 -1766. DOI: 10.1002/cac2.70077

LETTER TO THE JOURNAL

Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics

Author information +

¹. European Research Council Starting Grant, Targeting Genetic and Epigenetic Vulnerabilities in Solid Tumors and Sarcoma, National Institute of Health and Medical Research U981, Institut Gustave Roussy, Paris Saclay University, Villejuif, France

². Department of Pathology and Laboratory Medicine, Institut Gustave Roussy, Villejuif, France

³. Department of Therapeutic Innovation and Early Clinical Trials, Institut Gustave Roussy, Villejuif, France

⁴. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France

⁵. National Institute of Health and Medical Research 1052, French National Centre for Scientific Research 5286, Cancer Research Center of Lyon, Lyon, France

⁶. Division of Translational Pediatric Sarcoma Research (B410), German Cancer Research Center, German Cancer Consortium, Heidelberg, Germany

⁷. Hopp-Children's Cancer Center, Heidelberg, Germany

⁸. National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany

⁹. Somatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medicine, Institut Curie Hospital, Paris, France

¹⁰. Surgery Department, Institut Gustave Roussy, Villejuif, France

¹¹. Centre de Recherche des Cordeliers, Sorbonne University, National Institute of Health and Medical Research, Paris University, The French League Against Cancer, Paris, France

¹². Department of Pathology, Institut Bergonié, Bordeaux, France

¹³. Experimental and Translational Pathology Platform, Molecular Analysis, Modeling, and Imaging of Cancer, National Institute of Health and Medical Research US23/UAR3655, Institut Gustave Roussy, Villejuif, France

¹⁴. Paris Saclay University, Bicêtre Faculty of Medicine, Le Kremlin-Bicêtre, France

¹⁵. National Institute of Health and Medical Research U830, Integrative Functional Genomics of Cancer Lab, Paris Sciences & Lettres Research University, Institut Curie Research Center, Paris, France

¹⁶. Department of Translational Research, Paris Sciences & Lettres Research University, Institut Curie Research Center, Paris, France

¹⁷. Paris-Cité University & Expert Center in Childhood and Adolescent Oncology Center, National Institute of Health and Medical Research U830, Institut Curie Research Center, Paris, France

¹⁸. Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

¹⁹. University College of London Cancer Institute, London, UK

carine.ngo@gustaveroussy.fr

sophie.postel-vinay@gustaveroussy.fr

Show less

History +

PDF

Cite this article

Download citation ▾

Carine Ngo, Léo Colmet-Daage, Julien Vibert, Clémence Hénon, Daniel Pissaloux, Alexander Valent, Jia Xiang Jin, Riwan Brillet, Julien Masliah-Planchon, Gaëlle Pierron, Ludovic Lacroix, Etienne Rouleau, Cyril Roussel-Simonin, Lilian Lecorgne, Clémence Astier, Marlène Garrido, Rastislav Bahleda, Benjamin Verret, Axel Le Cesne, Charles Honore, Matthieu Faron, Wolf Herman Fridman, Catherine Sautès-Fridman, Jean-Michel Coindre, Jean-Yves Scoazec, Joshua J Waterfall, Franck Bourdeaut, Thomas G. P. Grünewald, Jean-Yves Blay, Franck Tirode, Sophie Postel-Vinay. Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics. Cancer Communications, 2025, 45(12): 1760-1766 DOI:10.1002/cac2.70077

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Grünewald TGP, Postel-Vinay S, Nakayama RT, Berlow NE, Bolzicco A, Cerullo V, et al. Translational Aspects of Epithelioid Sarcoma: Current Consensus. Clinical Cancer Research. 2024; 30(6):1079-92.

[2]	WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours, 5th ed.; WHO Classification of Tumours Series; International Agency for Research on Cancer: Lyon, France, 2020; 3.

[3]	Hornick JL, Dal Cin P, Fletcher CDM. Loss of INI1 Expression is Characteristic of Both Conventional and Proximal-type Epithelioid Sarcoma: The American Journal of Surgical Pathology. 2009;33(4):542-50.

[4]	Haefliger S, Chervova O, Davies C, Nottley S, Hargreaves S, Sumathi VP, et al. Subclassification of epithelioid sarcoma with potential therapeutic impact. The Journal of Pathology. 2023;260(4):368-75.

[5]	Rasmussen SV, Jin JX, Bickford LR, Woods AD, Sahm F, Crawford KA, et al. Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. Clinical & Translational Med. 2022;12(7):e961.

[6]	Sigalotti L, Frezza AM, Sbaraglia M, Del Savio E, Baldazzi D, Valenti B, et al. Proximal and Classic Epithelioid Sarcomas are Distinct Molecular Entities Defined by MYC/GATA3 and SOX17/Endothelial Markers, Respectively. Modern Pathology. 2025;38(1):100647.

[7]	Nakayama RT, Pulice JL, Valencia AM, McBride MJ, McKenzie ZM, Gillespie MA, et al. SMARCB1 is required for widespread BAF complex–mediated activation of enhancers and bivalent promoters. Nat Genet. 2017;49(11):1613-23.

[8]	Jin JX, Fuchslocher F, Carreno-Gonzalez M, Zahnow F, Ceranski AK, Will R, et al. Loss of SMARCB1 evokes targetable epigenetic vulnerabilities in epithelioid sarcoma. Cancer Commun (Lond). 2025;45(5):494-9.